Home › After Surgery › NCT05625373
The Effect of Intrawound Vancomycin Powder on Surgical Site Infection in Inguinal Lymph Node Dissection
Who can join
Ages 18 and older · Women · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Women who are undergoing inguinal lymph node dissection for vulvar dysplasia * Women with a prior lymph node dissection \>30 days before * Women undergoing either a sentinel lymph node biopsy or full lymphadenectomy in a unilateral or bilateral groin dissection Exclusion Criteria: * Known allergy to vancomycin * Known resistance to vancomycin
About the study
The study will be a pilot randomized control trial with a 1:1 patient randomization of vancomycin powder placement at the time of surgery (compared to no vancomycin placement) with the goal of reducing postoperative complications in patients undergoing an inguinal lymph node dissection for vulvar cancer. The primary objective is to measure the composite rate of postoperative complications within 30 days of inguinal lymph node dissection in patients with vulvar cancer.
What is being tested
- Vancomycin (drug)
Sponsor: Women and Infants Hospital of Rhode Island · Participants: 30 · Started: Oct 25, 2022
Contact the study team
- Jessica DiSilvestro, MD · Phone: 401-274-1100
Official record on ClinicalTrials.gov — NCT05625373
Locations in the U.S.
| Rhode Island | Women and Infants Hospital, Providence |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.